Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 26.5% in February

Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the target of a large drop in short interest in February. As of February 15th, there was short interest totalling 2,500 shares, a drop of 26.5% from the January 31st total of 3,400 shares. Based on an average trading volume of 10,500 shares, the days-to-cover ratio is currently 0.2 days.

Genenta Science Trading Up 1.9 %

Shares of GNTA traded up $0.08 during trading hours on Wednesday, hitting $3.94. The company had a trading volume of 1,520 shares, compared to its average volume of 8,205. Genenta Science has a one year low of $2.20 and a one year high of $7.28. The company's fifty day moving average price is $4.18 and its two-hundred day moving average price is $4.56.

Hedge Funds Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC acquired a new position in Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,167 shares of the company's stock, valued at approximately $46,000. Citadel Advisors LLC owned about 0.06% of Genenta Science as of its most recent SEC filing. 15.13% of the stock is owned by institutional investors and hedge funds.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.